Maria Farina-Morillas

Maria Farina-Morillas

Auto-generated profile, based on publicly available information

Maria Farina-Morillas

Vall d’Hebron Institute of Oncology 3 Cancer Computational Biology Group Barcelona, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
FHFloyd Hassenrück
Floyd Hassenrück
MFMaria Farina-Morillas
Maria Farina-Morillas
LNLars Neumann
Lars Neumann
FLFrancesco Landini
Francesco Landini
SBStuart James Blakemore
Stuart James Blakemore
GKGuenter Krause
Guenter Krause
Targeting the PI3K isoform p110δ against B cell malignancies is at the mainstay of PI3K inhibitor (PI3Ki) development. Therefore, we generated isogenic cell lines, which express wild type or mutant p110δ, for assessing the potency, isoform-selectivity and molecular interactions of various PI3Ki chemotypes. The affinity pocket mutation I777M maintains p110δ activity in the presence of idelalisib, as indicated by intracellular AKT phosphorylation, and rescues cell functions such as p110δ-dependent cell viability. Resistance owing to this substitution consistently affects the potency of p110δ-selective in contrast to most multi-targeted PI3Ki, thus distinguishing usually propeller-shaped and typically flat molecules. Accordingly, molecular dynamics simulations indicate that the I777M substitution disturbs conformational flexibility in the specificity or affinity pockets of p110δ that is necessary for binding idelalisib or ZSTK474, but not copanlisib. In summary, cell-based and molecular exploration provide comparative characterization of currently developed PI3Ki and structural insights for future PI3Ki design.

25 August 2025 in Epigenomics
Verified
Journal Article
Open access
MFMaria Farina-Morillas
Maria Farina-Morillas
LOLaia Ollé-Monràs
Laia Ollé-Monràs
SMSilvana Ce Maas
Silvana Ce Maas
IRIsabel de Rojas-P
Isabel de Rojas-P
Miguel F SeguraMiguel F Segura
Miguel F Segura
JSJose A. Seoane
Jose A. Seoane
Cancer treatment is an ongoing challenge, as directly targeting oncogenic drivers is often unfeasible in many patients due to the lack of druggable targets. This has led to the exploration of alternative strategies, such as exploiting synthetic lethality (SL) relationships between genes. SL facilitates the indirect targeting of oncogenic drivers, as exemplified by the clinical success of PARP inhibitors against BRCA-mutated tumors. Advances in high-throughput perturbation screens and multi-omics technologies have deepened our understanding of SL relationships, while computational models enhance SL predictions to better reflect biological complexity. However, while numerous experimental and computational methods have been developed to identify SL interactions, difficulties remain in translating these findings into clinical applications.This review combines recent progress on SL relationships in cancer with emerging insights into epigenetic regulation, highlighting how epigenetic drugs (epidrugs) can provide new opportunities for targeted interventions, offering a way to minimize off-target effects and enhance therapeutic precision. To advance SL-based therapies, efforts must focus not only on identifying new SL interactions but also on consolidating existing knowledge and integrating experimental and computational approaches to characterize the vulnerabilities of cancer cells. Strengthening this foundation will be critical for the effective development of SL-based cancer treatments.

14 May 2026 in Cancer Research
Verified
Journal Article
Closed access
SFSofia Ferreira
Sofia Ferreira
BFBrittany M. Flowers
Brittany M. Flowers
WCWonyoung Choi
Wonyoung Choi
MFMaria Farina-Morillas
Maria Farina-Morillas
AGAlberto Gatto
Alberto Gatto
LALaura D. Attardi
Laura D. Attardi
The CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, whereas ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. In this study, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models, Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC-suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial–mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content—hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC. Significance: ARF deficiency induced by CDKN2AARF alterations promotes remodeling of the pancreatic cancer microenvironment, which could provide a genotype-specific therapeutic vulnerability to improve outcomes of pancreatic cancer patients.

2 July 2026
Verified
Other
Open access
SFSofia Ferreira
Sofia Ferreira
BFBrittany M. Flowers
Brittany M. Flowers
WCWonyoung Choi
Wonyoung Choi
MFMaria Farina-Morillas
Maria Farina-Morillas
AGAlberto Gatto
Alberto Gatto
LALaura D. Attardi
Laura D. Attardi
Expression of Ink4a and a p53 tumor suppression-associated gene (TSAG) signature

2 July 2026
Verified
Other
Open access
SFSofia Ferreira
Sofia Ferreira
BFBrittany M. Flowers
Brittany M. Flowers
WCWonyoung Choi
Wonyoung Choi
MFMaria Farina-Morillas
Maria Farina-Morillas
AGAlberto Gatto
Alberto Gatto
LALaura D. Attardi
Laura D. Attardi
Analysis of PDAC development from adult mouse acinar cells across different Arf and Trp53 genotypes

2 July 2026
Verified
Other
Open access
SFSofia Ferreira
Sofia Ferreira
BFBrittany M. Flowers
Brittany M. Flowers
WCWonyoung Choi
Wonyoung Choi
MFMaria Farina-Morillas
Maria Farina-Morillas
AGAlberto Gatto
Alberto Gatto
LALaura D. Attardi
Laura D. Attardi
Identification of 4 groups within TCGA PAAD data.